

eIF4G (phospho-Ser1231) Conjugated Antibody

Catalog No: #C11514



Package Size: #C11514-AF350 100ul #C11514-AF405 100ul #C11514-AF488 100ul
 #C11514-AF555 100ul #C11514-AF594 100ul #C11514-AF647 100ul
 #C11514-AF680 100ul #C11514-AF750 100ul #C11514-Biotin 100ul

Orders: order@signalwayantibody.com
 Support: tech@signalwayantibody.com

Description

Product Name	eIF4G (phospho-Ser1231) Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Species Reactivity	Hu
Specificity	The antibody detects endogenous level of eIF4G only when phosphorylated at serine 1231.
Immunogen Description	Peptide sequence around phosphorylation site of serine 1231 (P-V-S(p)-P-L) derived from Human eIF4G.
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Accession No.	Swiss-Prot#:Q04637 NCBI Gene ID:1981 NCBI mRNA#:NM_004953.3 NCBI Protein#:NP_004944.2
Uniprot	Q04637
GeneID	1981;
Excitation Emission	AF350: 346nm/442nm AF405: 401nm/421nm AF488: 493nm/519nm AF555: 555nm/565nm AF594: 591nm/614nm AF647: 651nm/667nm AF680: 679nm/702nm AF750: 749nm/775nm
Calculated MW	220
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

Application Details

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250

AF405 conjugated: most applications: 1: 50 - 1: 250

AF488 conjugated: most applications: 1: 50 - 1: 250

AF555 conjugated: most applications: 1: 50 - 1: 250

AF594 conjugated: most applications: 1: 50 - 1: 250

AF647 conjugated: most applications: 1: 50 - 1: 250

AF680 conjugated: most applications: 1: 50 - 1: 250

AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

Product Description

Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.

Background

eIF4F is a multi-subunit complex, the composition of which varies with external and internal environmental conditions. It is composed of at least EIF4A, EIF4E and EIF4G1/EIF4G3. Interacts with eIF3, mutually exclusive with EIF4A1 or EIF4A2, EIF4E and through its N-terminus with PABPC1. Interacts through its C-terminus with the serine/threonine kinases MKNK1, and with MKNK2. Appears to act as a scaffold protein, holding these enzymes in place to phosphorylate EIF4E. Non-phosphorylated EIF4EBP1 competes with EIF4G1/EIF4G3 to interact with EIF4E; insulin stimulated MAP-kinase (MAPK1 and MAPK3) phosphorylation of EIF4EBP1 causes dissociation of the complex allowing EIF4G1/EIF4G3 to bind and consequent initiation of translation. EIF4G1/EIF4G3 interacts with PABPC1 to bring about circularization of the mRNA. Rapamycin can attenuate insulin stimulation mediated by FKBP. Interacts with EIF4E3. Interacts with MIF4GD. Interacts with rotavirus A NSP3; in this interaction, NSP3 takes the place of PABPC1 thereby inducing shutoff of host protein synthesis

Note: This product is for in vitro research use only